Article

Florida Cancer Specialists' Medical Oncologists Co-Author Analysis of Umbralisib in Lymphoid Malignancies

Three medical oncologists at Florida Cancer Specialists & Research Institute co-author a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

Fort Myers, FL – October 14, 2021–Florida Cancer Specialists & Research Institute (FCS) director of Clinical Research, Gustavo Fonseca, MD, FACP, director of Drug Development, Manish Patel, MD, and James Reeves, MD, a member of the FCS clinical research team, participated in a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

The study, “Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies,” was recently published online in Blood Advances.

Low rates of immune-mediated toxicities were observed with umbralisib and no cumulative toxicities were reported. The analysis concluded, “The favorable long-term tolerability profile and low rates of immune-mediated toxicities support the potential use of umbralisib for the benefit of a broad population of patients with lymphoid malignancies.”

Learn more.

Related Videos
Jonathan Eisengart
Robin Glasco, Spencer Stuart
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Screenshot of an interview with Nadine Barrett, PhD
Neil Goldfarb, GPBCH
Dr Bonnie Qin
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo